Mechanisms of Tirzepatide on Food Intake

What mechanistic pathways link tirzepatide to changes in calorie/food intake?

Tirzepatide reduces food intake through a layered set of mechanisms — peripheral satiety signaling, hypothalamic homeostatic circuits, hindbrain meal-termination/aversion circuits, and mesolimbic reward circuitry — with the GIP component contributing in ways that are mechanistically distinct from, and partly synergistic with, GLP-1R agonism. Most causal data are from rodents; the human evidence is largely behavioral and neuroimaging.

Peripheral: slowed gastric emptying (GLP-1R, not GIPR).

Tirzepatide delays gastric emptying, and both preclinical and clinical data attribute this to its GLP-1R component rather than GIPR. The effect peaks after the first doses and tachyphylaxes with continued dosing, paralleling other GLP-1 RAs and contributing more to early than to chronic intake suppression. A parallel mechanism — intestinal GLP-1 signaling onto vagal afferents projecting to the nucleus tractus solitarius (NTS) — drives earlier satiation and smaller meal size.

Hypothalamic AgRP/POMC neurons.

Fiber-photometry work in mice shows that pharmacologic activation of GIPR and GLP-1R acutely inhibits arcuate AgRP ("hunger") neurons and blunts their food-evoked responses; optogenetically re-driving AgRP activity partially rescues the anorexia induced by incretin agonism, implying AgRP inhibition is causally on-pathway. The same study found that physiological, nutrient-evoked AgRP inhibition required GIPR but not GLP-1R — GIPR antibody blocked glucose- and Ensure-driven AgRP suppression while exendin(9-39) did not. In other words, the GIP arm appears to carry the gut-nutrient signal into the hypothalamus, while both arms can be engaged pharmacologically. On the POMC side, tirzepatide sensitizes leptin signaling in hypothalamic POMC neurons and increases POMC firing by reducing inhibitory input, plausibly amplifying anorexigenic tone over time.

Hindbrain (dorsal vagal complex): meal termination and anti-aversive effects.

Fluorescently labeled tirzepatide penetrates the brain mainly at circumventricular organs, and both GLP-1R and GIPR in the dorsal vagal complex are required for the full synergistic body-weight effect of systemically dosed agonists. Within the area postrema, GIPR is expressed on GABAergic neurons that inhibit glutamatergic neurons promoting nausea/avoidance — including GFRAL+ and Glp1r+ cells. GIPR agonism in the hindbrain "can attenuate the aversive effects of GLP-1RA by directly suppressing the neural activities underlying aversive behaviors." This anti-aversive action is one of the better-supported explanations for why tirzepatide can produce greater intake/weight reduction than GLP-1 monoagonists without proportionally worse nausea — it raises the ceiling on tolerable anorectic drive.

Mesolimbic reward circuitry.

GLP-1R-expressing neurons in the central amygdala project to VTA dopamine neurons; activating this CeA→VTA pathway blunts nucleus-accumbens dopamine transients during palatable-food consumption and selectively reduces high-fat-diet intake in mice. In humans, the phase 1 trial reported a 523 kcal reduction in ad libitum lunch intake at week 3 vs placebo (treatment difference −534 kcal, p<0.0001) accompanied by decreased BOLD activation to high-fat/high-sugar food images in medial frontal gyrus, cingulate gyrus, hippocampus, and orbitofrontal cortex — regions encoding food reward value and inhibitory control. Tirzepatide also reduced cravings, disinhibition, and Power-of-Food scores; liraglutide at the same time point did not show the corresponding BOLD reductions. The authors caution that selective GIP agonists/antagonists aren't available in humans, so the GIP vs. GLP-1 contribution to these neuroimaging effects can't be cleanly separated.

GIP vs GLP-1 contribution — the synthesis.

Tirzepatide is an "imbalanced" agonist with higher affinity for human GIPR than GLP-1R. Cotreatment with GIPR and GLP-1R agonists reduces food intake and body weight more than either alone, and CNS-specific loss of GIPR ablates the additional weight loss of dual agonism beyond what GLP-1R agonism produces. The most coherent account is that GLP-1R handles peripheral gastric slowing and a large share of central anorexia, while CNS GIPR (a) directly engages a partly distinct hypothalamic/hindbrain neuronal population, (b) mediates physiological nutrient-evoked AgRP inhibition, and (c) suppresses aversion in the area postrema, indirectly enabling more anorectic drive to translate into intake reduction.

Caveats

Most circuit-level causality (AgRP photometry, CeA→VTA, AP GABAergic anti-aversion, DVC knockouts) is rodent. Human evidence is restricted to behavioral readouts, ad libitum meal tests, fMRI to food cues, and inferences from comparator GLP-1 RAs — and the field still can't formally partition GIP vs GLP-1 contributions in humans without a selective GIP tool compound.